North American adult T-cell leukemia/lymphoma (NA-ATLL) has poor outcomes and limited therapeutic options. In a small case series, peginterferon-alfa-2a plus bictegravir/emtricitabine/tenofovir alafenamide, with selective venetoclax, suppressed HTLV-1, reduced circulating ATLL burden, supporting the prospective evaluation of this treatment modality.